Search
Rindopepimut
go.drugbank.com/drugs/DB05374InvestigationalRindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).
Nirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146] It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and neutralizes several RSV A and B strains.
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist.
Rucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigational[A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. … On December 17, 2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexCloxazolam
go.drugbank.com/drugs/DB01553ExperimentalAs well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness. … Although less commonly noted, it has also been reported as clinically effective in the treatment of depression, schizophrenia, and neurosis.
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. … [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, MATE 2 Substrates with a Narrow Therapeutic IndexDichlorotetrafluoroethane
go.drugbank.com/drugs/DB20118ApprovedWithdrawnDichlorotetrafluoroethane is a small molecule drug. Dichlorotetrafluoroethane has a monoisotopic molecular weight of 169.93 Da.
Iopydone
go.drugbank.com/drugs/DB20831ApprovedWithdrawnIopydone is a small molecule drug. Iopydone has a monoisotopic molecular weight of 346.83 Da.
Methysergide
go.drugbank.com/drugs/DB00247ApprovedWithdrawnAn ergot derivative that is a congener of lysergic acid diethylamide. … It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids.
Synonyms: 1-Methyl-D-lysergic acid butanolamide, (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamideCategories: Heterocyclic Compounds with 4 or More RingsTranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalTranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. … It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.